Group 1 - The Hong Kong Stock Exchange has launched the Hong Kong Stock Exchange Technology 100 Index, which tracks the performance of the 100 largest technology companies listed on the exchange, covering six major innovation themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1] - The index includes only stocks that qualify for the Stock Connect program, catering to both international and mainland Chinese investors [1] - Lijun Pharmaceutical Group has been selected as one of the first constituent stocks of the Hong Kong Stock Exchange Technology 100 Index, highlighting its strong performance in the biopharmaceutical sector [2] Group 2 - Lijun Pharmaceutical, listed on both the Shenzhen Stock Exchange and the Hong Kong Stock Exchange, has distinguished itself through its deep expertise in biomedicine, continuous R&D investment, and strong market performance [2] - The inclusion in the Technology 100 Index is seen as a recognition of the company's commitment to technological innovation and high-quality development, enhancing its visibility and influence in the international capital market [2] - This recognition is expected to encourage Lijun Pharmaceutical to continue its focus on R&D innovation and expedite the development of its pipeline, further solidifying its core competitiveness in the biopharmaceutical field [2]
丽珠医药获纳入港交所科技100指数首批成份股 创新实力获资本市场认证